Mokhtari Fedra, Mohebbi Seyed Reza, Sharifian Afsaneh, Ramandi Marzieh, Razzaghi Mohammad Reza
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2021 Fall;14(Suppl1):S10-S23.
The liver plays a principal role in the human body as a metabolic and detoxifying unit. Liver diseases are the world's major health problems and affect millions of people worldwide. Early detection of liver diseases is certainly effective in timely treatment and prevention of their progression. Liver injury is associated with significant alterations in immune responses and pattern changes in various tissue-related gene expressions and cytokine production. Increasing or decreasing the specific spectrum of non-coding RNAs in different phases of liver disease can be a criterion for diagnosis. Novel diagnostic biomarkers are needed for liver diseases. Currently, micro-RNAs (miRNAs) are known to play important roles in the diagnosis of liver diseases. Circulating biomarkers such as miRNA-assisted diagnosis can conceivably be helpful for the early treatment of liver diseases. In this review, we look at miRNAs and their potential applications in liver diseases as diagnostic biomarkers were investigated.
肝脏作为人体的代谢和解毒器官发挥着主要作用。肝脏疾病是全球主要的健康问题,影响着世界各地数百万人。早期发现肝脏疾病对于及时治疗和预防其进展肯定是有效的。肝损伤与免疫反应的显著改变以及各种组织相关基因表达和细胞因子产生的模式变化有关。在肝脏疾病的不同阶段增加或减少非编码RNA的特定谱可以作为诊断标准。肝脏疾病需要新的诊断生物标志物。目前,已知微小RNA(miRNA)在肝脏疾病的诊断中发挥重要作用。诸如miRNA辅助诊断等循环生物标志物可能有助于肝脏疾病的早期治疗。在这篇综述中,我们研究了miRNA及其在肝脏疾病中作为诊断生物标志物的潜在应用。